Apellis Pharmaceuticals, Inc. (APLS)
- Previous Close
19.98 - Open
19.76 - Bid 15.33 x 200
- Ask 20.75 x 200
- Day's Range
18.99 - 20.18 - 52 Week Range
16.98 - 44.12 - Volume
3,475,241 - Avg. Volume
2,200,255 - Market Cap (intraday)
2.511B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-1.53 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.50
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
apellis.comRecent News: APLS
View MorePerformance Overview: APLS
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLS
View MoreValuation Measures
Market Cap
2.40B
Enterprise Value
2.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.03
Price/Book (mrq)
10.51
Enterprise Value/Revenue
3.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.33%
Return on Assets (ttm)
-12.32%
Return on Equity (ttm)
-93.55%
Revenue (ttm)
781.37M
Net Income Avi to Common (ttm)
-197.88M
Diluted EPS (ttm)
-1.53
Balance Sheet and Cash Flow
Total Cash (mrq)
416.14M
Total Debt/Equity (mrq)
205.56%
Levered Free Cash Flow (ttm)
-35.7M